342 related articles for article (PubMed ID: 17332279)
1. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
2. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
3. [Clinical development of PARP inhibitors].
Toyoda M; Minami H
Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
6. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
7. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
8. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
9. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
10. Toward specific functions of poly(ADP-ribose) polymerase-2.
Yélamos J; Schreiber V; Dantzer F
Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Jagtap P; Szabó C
Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
[TBL] [Abstract][Full Text] [Related]
16. Differential contribution of poly(ADP-ribose)polymerase-1 and -2 (PARP-1 and -2) to the poly(ADP-ribosyl)ation reaction in rat primary spermatocytes.
Tramontano F; Malanga M; Quesada P
Mol Hum Reprod; 2007 Nov; 13(11):821-8. PubMed ID: 17766683
[TBL] [Abstract][Full Text] [Related]
17. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
18. Poly ADP-ribose polymerase-1 and health.
Kirkland JB
Exp Biol Med (Maywood); 2010 May; 235(5):561-8. PubMed ID: 20463295
[TBL] [Abstract][Full Text] [Related]
19. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
20. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
